HQL News and Press, TeklaLife Sciences Investors From 04/22/20

Closed-end-funds offer investors exposure to actively managed investment portfolios that oftentimes feature more dynamic strategies compared to passive ETFs. While many investors are attracted to the income profile of the various funds with corresponding impressively high yields and managed ...

In my last article, I advanced my current strategy for investing in global and emerging markets closed-end funds. Since its publication all heck has broken loose in our private lives, our employment situations, in the investment arenas, and, for some in areas pertaining to our personal health....

Author's note: This article was initially released to CEF/ETF Income Laboratory members on February 10, 2020. Please check latest data before investing. Chemist's Closed-End Fund Report Quantitative screens help to rapidly narrow down attractive candidates from the database of 500-plus...

Foreword Any collection of stocks is more clearly understood when subjected to yield-based (dog catcher) analysis, these dividend-boosted batches are perfect for the Arnold dog catcher process. Here is your February 24 data from Barron's for 88 dividend-paying stocks as supplemented by dog...

Despite the coronavirus concerns that have hit commodity markets and, in turn, energy and basic materials stocks, U.S. tech stocks have posted strong returns to start the year. This continues their impressive streak from 2019. But are the current tech valuations sustainable? In a recent mark...

By Vinay Thapar and Frank Caruso US healthcare is always a political hot potato, and volatility is expected to rise as the November elections approach. But investors can find good opportunities in the sector in companies with strong long-term business drivers that are relatively immune to ...

Tekla Life Sciences Fund ( HQL ) frequently makes the cut as my Top Pick for more conservative investors — thanks to its generous distribution policy, explains Nate Pile , editor of Nate's Notes . Meanwhile, the fact that the biotech sector happens to be on fire at t...

Despite the biotech industry having pockets of extreme and irrational ebullience, the largest part of the industry is systematically underfunded. It's also the highest-value-add part of the industry from a risk-adjusted basis. In this video, we have a philosophical discussion with the CEO of o...

It's time to talk about a new venture called EQRx. This has made quite a splash in the last few days at the JPMorgan investor conference, and it's been launched by Alexis Borisy (involved with founding and/or helping run CombinatoRx, Foundation, Blueprint, WarpDrive Bio, Editas, Relay, and oth...

Author's note : This article was released to CEF/ETF Income Laboratory members on December 17, 2019. Chemist's Closed-End Fund Report Quantitative screens help to rapidly narrow down attractive candidates from the database of 500-plus closed-end funds [CEFs] for further due diligence ...